Xeris Biopharma director logs grant and share sale

Xeris Biopharma Holdings director John Johnson reported a mix of equity awards and a pre-planned share sale.

Rhea-AI Filing Summary

Xeris Biopharma Holdings director John Johnson reported a mix of equity awards and a pre-planned share sale. He received 24,193 shares of common stock through a restricted stock unit grant and 32,996 stock options with a $6.15 exercise price, both vesting in full on the earlier of June 4, 2026 or the company’s next annual stockholder meeting, subject to continued service.

On the same date, he sold 15,000 common shares at a weighted average price of $6.0948 per share under a Rule 10b5-1 trading plan adopted on August 13, 2025. After these transactions, he directly holds 707,276 common shares and 32,996 stock options.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 3 txns

Insider JOHNSON JOHN

Role Director

Sold 15,000 shs ($91K)

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,996	$6.15	$203K
Sale	Common Stock	15,000	$6.0948	$91K
Grant/Award	Common Stock	24,193	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 32,996 contracts (Direct); Common Stock — 707,276 shares (Direct)

Footnotes (4)

1. F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
4. F4. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Key Figures

RSU shares granted: 24,193 shares Shares sold: 15,000 shares Sale price (weighted average): $6.0948 per share +5 more

8 metrics

RSU shares granted 24,193 shares Restricted stock unit grant of common stock

Shares sold 15,000 shares Open-market sale of common stock

Sale price (weighted average) $6.0948 per share Weighted average sale price for 15,000 shares

Options granted 32,996 options Stock options on common stock granted

Option exercise price $6.15 per share Stock option conversion or exercise price

Option expiration June 4, 2036 Expiration date of granted stock options

Common shares held after 683,083 shares Direct common stock holdings after transactions

Options held after 32,996 options Direct option holdings after transactions

Key Terms

Rule 10b5-1 trading plan, restricted stock unit, weighted average price, 2018 Stock Option and Incentive Plan, +1 more

5 terms

Rule 10b5-1 trading plan financial

"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock unit financial

"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan")."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

2018 Stock Option and Incentive Plan financial

"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan")."

vest in full financial

"These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date."

FAQ

What insider transactions did Xeris Biopharma (XERS) director John Johnson report?

John Johnson reported receiving restricted stock units and stock options, plus selling shares. He was granted 24,193 common shares, 32,996 options at $6.15, and sold 15,000 shares at a weighted average $6.0948 on the same date.

How many Xeris Biopharma (XERS) shares does John Johnson hold after the Form 4?

After the reported transactions, John Johnson directly holds 683,083 shares of Xeris Biopharma common stock. This reflects his equity position following the grant of restricted stock units and an open-market sale of 15,000 shares under a trading plan.

What equity awards did John Johnson receive from Xeris Biopharma (XERS)?

John Johnson received 24,193 common shares via a restricted stock unit grant and 32,996 stock options. The options carry a $6.15 exercise price and both the RSUs and options vest in full upon the earlier of June 4, 2026 or the next annual meeting.

At what price did John Johnson sell Xeris Biopharma (XERS) shares?

He sold 15,000 Xeris Biopharma common shares at a weighted average price of $6.0948 per share. The sale occurred in multiple trades within a $5.970 to $6.170 range, according to the reported Form 4 transaction footnote.

Was John Johnson’s Xeris Biopharma (XERS) share sale pre-planned?

Yes. The sale of 15,000 Xeris Biopharma shares was executed under a Rule 10b5-1 trading plan. The footnotes state this plan was adopted on August 13, 2025, indicating the sale was pre-arranged rather than a discretionary market-timing decision.

When will John Johnson’s new Xeris Biopharma (XERS) RSUs and options vest?

Both the 24,193 restricted stock units and 32,996 stock options vest in full upon the earlier of June 4, 2026 or the date of Xeris Biopharma’s next annual stockholder meeting, provided John Johnson continues his service through that vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 06:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON JOHN

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		S(1)		15,000	D	$6.0948(2)	683,083	D
Common Stock	06/04/2026		A		24,193(3)	A	$0	707,276	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.15	06/04/2026		A		32,996		(4)	06/04/2036	Common Stock	32,996	$6.15	32,996	D

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

4. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Remarks:

	/s/ Beth Hecht, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)